Released May 5, 2020, after the close
10-Q filed May 5, 2020, 35 days after period end · 0001558370-20-005179
Q1 2020 · 10-Q
Revenue$55.76M$55.76M +341.7% vs Q1 2019+262.1% vs Q4 2019
Net Income$21.24M$21.24M N/M vs Q1 2019N/M vs Q4 2019
EPS Diluted$0.13$0.13 N/M vs Q1 2019N/M vs Q4 2019
Gross Profit$12,525,000+57.6%
Operating Income$21,027,000N/M
Operating Cash Flow-$3,093,000N/M
Free Cash Flowderived-$3,700,000N/M
Margins · derived
Gross margin22.5%−40.5 pt vs Q1 2019
Operating margin37.7%+183.3 pt vs Q1 2019
Net margin38.1%+177.5 pt vs Q1 2019
What the release said
The release
Same quarter
| Metric | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|
| Revenue | $55.76M | $12.62M | — | $3.58M |
| Net Income | $21.24M | -$17.60M | -$24.39M | -$15.31M |
| EPS Diluted | $0.13 | -$0.11 | -$0.17 | -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR